DPP-4 inhibitor anagliptin protects against hypoxia-induced cytotoxicity in cardiac H9C2 cells
Source abstract
Abstract
Cardiovascular complications are the leading cause of mortality and morbidity in type 2 diabetes patients. Diabetes greatly increases the risk of heart disease; therefore, the management of diabetes often involves the prevention of heart disease. DPP-4 inhibitors have been proven to be the effective therapeutic agents of glycaemic control. Recent studies have shown that certain types of DPP-4 inhibitors could also have cardiovascular benefits. In this study, we examined the protective role of the newly developed DPP-4 inhibitor anagliptin in cultured cardiac myocytic cell line H9C2 cells. Our data show that exposure of H9C2 cells to hypoxic conditions induced higher expression of DPP-4, indicating that DPP-4 is a hypoxia-inducible factor. The inhibition of DPP-4 by anagliptin ameliorates hypoxia-induced cytotoxicity and induction of the pro-inflammatory cytokines IL-6 and MCP-1. Anagliptin also suppresses hypoxia-induced oxidative stress as revealed by the detected levels of cellular ROS and reduced GSH. Moreover, anagliptin protects myocytes from hypoxia-associated reduced mitochondrial membrane potential. Mechanistically, we show that anagliptin promotes hypoxia-induced NFR2/HO1 induction but suppresses HMGB1 and MyD88 generation. Collectively, our data indicate that anagliptin-mediated DPP-4 inhibition is a protective mechanism in cardiomyocytes and imply that the DDP-4 inhibitor anagliptin plays dual roles by lowering glucose and protecting cardiomyocytes.
Source: openalex_inverted_index · Quality: baseline
Research context
OpenAlex topics: Diabetes Treatment and Management · Metabolism, Diabetes, and Cancer · Neuropeptides and Animal Physiology
SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.
Affiliations
Southern Medical University Affiliated Fengxian Hospital
Tengzhou Central People's Hospital
Shanghai University of Medicine & Health Sciences
Funding
Shanghai Science and Technology Commission
References (30)
Show source-provided references
1. 10.2337/diabetes.54.6.161510.2337/diabetes.54.6.1615 ↗
2. 10.2337/diacare.26.2007.S3310.2337/diacare.26.2007.S33 ↗
3. 10.1517/14656566.2013.82496610.1517/14656566.2013.824966 ↗
4. 10.1161/CIRCULATIONAHA.117.02813610.1161/CIRCULATIONAHA.117.028136 ↗
5. 10.1016/j.amjcard.2017.05.01510.1016/j.amjcard.2017.05.015 ↗
6. 10.1080/07853890.2017.133542810.1080/07853890.2017.1335428 ↗
7. 10.1016/j.vph.2018.05.01010.1016/j.vph.2018.05.010 ↗
8. 10.1016/j.bmc.2011.09.04310.1016/j.bmc.2011.09.043 ↗
9. 10.1210/en.2012-185510.1210/en.2012-1855 ↗
10. 10.3892/mmr.2017.766710.3892/mmr.2017.7667 ↗
11. 10.1161/JAHA.116.00477710.1161/JAHA.116.004777 ↗
12. 10.1536/ihj.16-54710.1536/ihj.16-547 ↗
13. 10.2147/DMSO.S5467910.2147/DMSO.S54679 ↗
14. 10.14740/jocmr3464w10.14740/jocmr3464w ↗
15. 10.1007/s10863-018-9746-z10.1007/s10863-018-9746-z ↗
16. 10.1007/s10863-014-9598-010.1007/s10863-014-9598-0 ↗
17. 10.1007/s10863-019-09792-w10.1007/s10863-019-09792-w ↗
18. 10.1172/JCI20052440810.1172/JCI200524408 ↗
19. 10.1016/j.bbamcr.2014.11.01510.1016/j.bbamcr.2014.11.015 ↗
20. 10.1155/2014/26042910.1155/2014/260429 ↗
21. 10.1161/CIRCRESAHA.116.30658810.1161/CIRCRESAHA.116.306588 ↗
22. 10.1007/s00395-014-0450-910.1007/s00395-014-0450-9 ↗
23. 10.1007/s13238-012-2063-010.1007/s13238-012-2063-0 ↗
24. 10.1186/s12872-017-0704-110.1186/s12872-017-0704-1 ↗
25. 10.1016/j.biopha.2018.10.03510.1016/j.biopha.2018.10.035 ↗
26. 10.1016/j.molimm.2019.01.00610.1016/j.molimm.2019.01.006 ↗
27. 10.1016/j.biopha.2018.04.18710.1016/j.biopha.2018.04.187 ↗
28. 10.1016/j.freeradbiomed.2018.04.58010.1016/j.freeradbiomed.2018.04.580 ↗
29. 10.1007/s00125-016-4071-810.1007/s00125-016-4071-8 ↗
30. 10.1007/s10557-018-6776-z10.1007/s10557-018-6776-z ↗